Compare LXFR & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXFR | EOLS |
|---|---|---|
| Founded | 1898 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.4M | 407.0M |
| IPO Year | 2002 | 2018 |
| Metric | LXFR | EOLS |
|---|---|---|
| Price | $19.23 | $6.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 133.4K | ★ 755.8K |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $384,600,000.00 | $297,176,000.00 |
| Revenue This Year | N/A | $13.27 |
| Revenue Next Year | $5.01 | $17.62 |
| P/E Ratio | $146.77 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $11.19 | $3.86 |
| 52 Week High | $19.25 | $10.20 |
| Indicator | LXFR | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 78.91 | 51.32 |
| Support Level | $11.64 | $6.44 |
| Resistance Level | N/A | $6.52 |
| Average True Range (ATR) | 0.71 | 0.36 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 86.64 | 49.05 |
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.